Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Angela Duffy
  • March 18, 2020
  • Articles

Mapping the patient journey and minding the gap: Seven steps to closing the gap between rhetoric and reality in patient-centricity

Mapping the patient journey and minding the gap: Seven steps to closing the gap between rhetoric and reality in patient-centricity

Senior Director Angela Duffy was recently interviewed by PME Magazine about the steps needed to close the gap between rhetoric and reality in patient-centricity, and why it’s vital to include patients in every step.

“When I grew up in the industry, things were pretty well set in terms of how pharmaceutical companies engaged with patients - which is to say that you didn’t engage all that much.” Ron Cohen’s reflection on ‘Pharma Past’ will be familiar to many who worked in the industry in the era before patient-centricity became the biggest of buzzwords. Speaking to McKinsey in 2016, the biotech CEO argued that a new generation of engagement was dawning. 

read more »

How multi-stakeholder patient journey insights in oncology were brought to life with creative outputs and data visualisation

How multi-stakeholder patient journey insights in oncology were brought to life with creative outputs and data visualisation

Two clients were co-developing a product and needed to understand the patient journey in two areas of oncology, in order to identify the leverage points where they could provide an improved patient experience.
We carried out qualitative research with all relevant stakeholders - patients, caregivers, oncologists, haematologists and nurses in all the markets in order to get a 360 degree view of the patient journey, triangulate different viewpoints and understand where disconnects existed between stakeholders.  

read more »

  • Posted by Pei Li Teh & Wan Ling Neo
  • November 15, 2019
  • Articles

Launching novel oncology therapies in Asia: Identifying and communicating value

Launching novel oncology therapies in Asia: Identifying and communicating value

Novel cancer therapies are offering patients new treatments and better outcomes worldwide. Recent changes in healthcare policies across APAC have reignited interest in the region as a strong market for oncology, such as China's fast tracking approval of therapies for severe and rare diseases and Vietnam's plan to cover health insurance for 80% of the population. Unfortunately, the often eye-watering costs of these new therapies means that, currently, for the many patients who still have to pay for treatment out of pocket, novel therapies are beyong reach. Pharma brands need to demonstate clear value if they want to achieve success. 

read more »

  • Posted by Marc Yates
  • March 21, 2017
  • Events

Pharma China Annual Forum 2017

Pharma China Annual Forum 2017

We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.

We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China. Representing Research Partnership will be Asia Pacific Director and emerging markets specialist Pei Li Teh, who will be presenting the paper ’Urban China’s Evolving Patient Journey’ from 14:30 – 15:00.

read more »

Understanding the chronic disease patient journey in emerging markets

Understanding the chronic disease patient journey in emerging markets

In this paper, we explore the chronic disease patient journey in emerging markets and provide you with the insights you require to identify the key inflection points in these rapidly changing and diverse regions.

With growing urban populations and increasing purchasing power, emerging markets remain an attractive prospect for growth. A high proportion of the urban emerging market population already suffers from chronic diseases and prevalence is set to further increase as lifestyles become closer to those in the West. The chronic disease patient is a critical stakeholder in emerging markets because they often have to pay for their healthcare out of pocket. Moreover, these markets often don’t have formal primary care systems, so the patient is the only constant in the journey. Understanding their journey is critical in order to best leverage these potential new markets.

read more »